DCM
PFE icon

Deuterium Capital Management’s Pfizer PFE Stock Holding History

Deuterium Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,565
Closed -$541K – 102
2022
Q4 		$541K Buy
10,565
+5,789
+121% +$278K 1.43% 15
2022
Q3 		$209K Sell
4,776
-4,741
-50% -$230K 0.87% 23
2022
Q2 		$499K Hold
9,517
– – 1.69% 15
2022
Q1 		$493K Buy
+9,517
New +$494K 0.63% 29

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deuterium Capital Management's PFE Position: Q1 2023 in Review

Deuterium Capital Management sold out of Pfizer (PFE) in Q1 2023, closing a stake of 10,565 shares — an estimated $541K sold.

Deuterium Capital Management first reported a position in PFE in Q1 2022 and held it in 4 quarters. The position peaked at $541K in Q4 2022. 3,103 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Deuterium Capital Management reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Deuterium Capital Management sold 10,565 Pfizer shares in Q1 2023, an estimated $541K.
  • Deuterium Capital Management first reported a position in Pfizer in Q1 2022 and held it in 4 quarters.
  • Deuterium Capital Management's Pfizer position peaked at $541K in Q4 2022.
  • 3,103 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Deuterium Capital Management's 13F filing for Q1 2023, filed 12 May 2023.